TABLE 1.

Participant demographic and baseline characteristics

Mavorixafor + Pembrolizumab (N = 16)
Age (years)	Mean (± SD) Median (min, max)	74.6 (± 9.6) 74.5 (53, 91)
Gender	Male Female	10 (62.5%) 6 (37.5%)
Ethnicity	Not Hispanic or Latino	16 (100%)
Race	White Asian	15 (93.8%) 1 (6.3%)
Screening ECOG status	0 1	9 (56.3%) 7 (43.8%)
Disease Characteristics (N = 16) N (%)
Resectable Disease	Yes No	10 (62.5) 6 (37.5)
Stage of Disease Enrollmenta	IIIB IIIC IV M1A	4 (25.0) 10 (62.5) 2 (12.5)
Prior systemic therapies	0 1	15 (93.8) 1 (6.3)

Abbreviations: ECOG, Eastern Cooperative Oncology Group; SD, standard deviation.

^aper AJCC 7th Edition.